Vidac Pharma Holding Plc

€0.20As of Sun 8 Nov 2026, 12:00 UTC

XETRA:T9GHealthcare

Country Germany

PE (Fwd) —

TSR 10Y CAGR —

Div yield —

ROE (617.65%)

Biotechnology

Beta (5Y) —

PE TTM —

TSR TTM —

Mkt cap €11.56M

ROIC (561.60%)

SE Grade™

—

Value

—

Quality

Moat

—

1Y Price

Reference

€0.218

—

7.39%

—

TTM

FYE 31 Dec EUR

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

◌—

Revenue€M

—

◌—

—

◌—

—

Revenue growth%

—

Gross margin%

—

Operating margin%

—

Net margin%

—

P/E ratio (avg)x

—

EV/EBITx

—

(0.01)

FCF yield (avg)%

—

FCF margin%

—

0.917

FCF / Net incomex

—

0.728

0.535

—

0.917

—

0.728

—

(561.60)

ROIC%

—

(561.60)

—

(561.60)

—

(617.65)

Return on equity%

—

(617.65)

—

(617.65)

—

(288.11)

Return on assets%

—

(1368.09)

(1071.43)

—

(288.11)

—

(1071.43)

—

EPS€

—

(0.01)

—

EPS growth%

—

99.80

—

99.80

—

Bookvalue per sh€

—

(0.01)

—

FCF per share€

—

(0.01)

—

Dividend per sh€

—

Div yield (avg)%

—

Payout ratio%

—

56.95

Shares (diluted)B

—

0.054

52.82

54.58

56.95

◌56.95

919.03%

—

(4.34)

Buyback yield%

—

(98052.81)

(3.33)

(4.34)

◌—

(4.34)

—

(0.498)

D/E ratiox

—

(0.555)

(0.188)

—

(0.498)

—

11.56

Enterprise value€B

—

11.56

—

LT debt€M

—

Peers (US$23.19M)

Cap (US$)

ImmuPharma plc

27.68M

—

Oxford BioDynamics Plc

18.09M

—

SkinBioTherapeutics plc

17.44M

—

HLB Pep Co., Ltd.

23.50M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

—

Own earn%

—

Sh yield%

(4.34)

Owners

Insiders/Inst%

89.50

—

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

0/3

Revenue growth years

—

EPS growth years

—

Dividend streakyrs

Op margin range%

—

$1 testx

—

Incr. ROIC%

—

Vidac Pharma Holding Plc, an investment holding company, engages in the discovery and development of anticancer medicines.

Revenue by segment

No breakdown available

Asset mix

Trend

Other

61.89%

Cash and investments

38.11%

Reinvestment returns

No breakdown available